Business methods useful for identifying, and marketing or commercializing glycomics-related diagnostic, therapeutic and/or imaging probe products are disclosed. Patient test samples are screened for the presence of glycan-binding moieties to produce binding data. Binding data is collected into a database. One or more bioinformatic algorithms are used to process the collected binding data to identify one or more diagnostic, therapeutic or imaging probe products. Identified products are collaboratively or independently, marketed or commercialized. Business methods are also provided for marketing or commercializing products for producing oligosaccharides, reactive antibody products, and monoclonal antibody cocktail products. Business methods of conducting glycomics-related cancer trials are also disclosed.